Groen Harald C, Wit Esther M K, Heerink Wouter J, Kuhlmann Koert F D, Nijkamp Jasper A, van Veen Ruben, Schoots Ivo G, Balduzzi Sara, Zijlmans Henry J M A A, van Leeuwen Pim J, van der Poel Henk G, Ruers Theo J M
Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
EClinicalMedicine. 2024 Jul 26;74:102754. doi: 10.1016/j.eclinm.2024.102754. eCollection 2024 Aug.
Metastatic retroperitoneal lymph node dissection (LND) for nodal recurrence is applied for a variety of cancers, such as urological, gynaecological and rectal cancer. Precise localisation and resection of these lymph nodes (LNs) during surgery can be challenging, especially after previous radiotherapy or surgery. The objective of this study was to assess the added value of surgical navigation for targeted LND in the retroperitoneum.
We performed an open-label randomised, controlled, phase 3 trial at the Netherlands Cancer Institute, Amsterdam. Eligible participants were over 18 years of age, scheduled for targeted retroperitoneal LND by laparotomy, with removal of one or more suspected (targeted) LN(s) as assessed by diagnostic imaging. Patients were randomised (1:1) between conventional LND and LND using surgical navigation, by means of a minimisation method stratified for tumour origin (urological, colorectal and other). For the surgical navigation, a digital 3D model of the patients' anatomy was created from diagnostic CT scans, including delineation of the targeted LN(s). The 3D model was linked to the patients' position in the operation room. Using an electromagnetic tracking system, with a sterile tracked pointer, the actual position of the pointer was shown in the 3D model, enabling the surgeon to localize the targeted LN(s). The primary outcome of the study was the percentage of successful procedures. Success was defined as no residual target LN(s) visible on postoperative CT imaging. This study was registered with ClinicalTrials.gov, NCT05867095.
From January 2017 to December 2020, 69 participants were included in the study, 35 (51%) in the conventional arm and 34 (49%) in the navigation arm. Four patients were not evaluable and excluded from further analysis; three in the conventional arm (patients withdraw from study participation), one in the navigation arm (discontinued surgery, misclassified diagnosis). According to intention-to-treat analysis, 50% (16/32) of the surgical procedures was successful in the conventional arm, versus 85% (28/33) in the surgical navigation arm (one-tailed p = 0.0028, 90% CI: 14%-56%). Using the Clavien-Dindo classification, the overall complication rate was comparable between the conventional arm and the navigation arm. Surgeons judged the surgical navigation setup as valuable, the median preference score to use surgical navigation was 3.7 (3.3-4.0) (scale 1-5), and the median system usability score was 75 (70-85) (scale 0-100).
Surgical navigation allows for significantly better localisation and removal of target LN(s) in the retroperitoneum.
This research was supported by the KWF-Alpe d'HuZes (NKI 2014-6596) and by an institutional grant of The Dutch Cancer Society and of the Dutch Ministry of Health, Welfare and Sport.
转移性腹膜后淋巴结清扫术(LND)用于治疗多种癌症的淋巴结复发,如泌尿系统、妇科和直肠癌。手术中对这些淋巴结(LN)进行精确的定位和切除具有挑战性,尤其是在既往接受过放疗或手术的情况下。本研究的目的是评估手术导航在腹膜后靶向LND中的附加价值。
我们在阿姆斯特丹的荷兰癌症研究所进行了一项开放标签的随机对照3期试验。符合条件的参与者年龄超过18岁,计划通过剖腹手术进行靶向腹膜后LND,根据诊断成像评估切除一个或多个疑似(靶向)LN。患者通过最小化方法按肿瘤起源(泌尿系统、结直肠和其他)分层,在传统LND和使用手术导航的LND之间随机分组(1:1)。对于手术导航,根据诊断CT扫描创建患者解剖结构的数字3D模型,包括靶向LN的描绘。3D模型与患者在手术室中的位置相关联。使用电磁跟踪系统和无菌跟踪指针,指针的实际位置显示在3D模型中,使外科医生能够定位靶向LN。本研究的主要结局是成功手术的百分比。成功定义为术后CT成像上未见残留的靶向LN。本研究已在ClinicalTrials.gov注册,NCT05867095。
2017年1月至2020年12月,69名参与者纳入研究,传统组35名(51%),导航组34名(49%)。4名患者不可评估,被排除在进一步分析之外;传统组3名(患者退出研究),导航组1名(手术中止,诊断错误分类)。根据意向性分析,传统组手术成功率为50%(16/32),手术导航组为85%(28/33)(单尾p = 0.0028,90%CI:14%-56%)。使用Clavien-Dindo分类法,传统组和导航组的总体并发症发生率相当。外科医生认为手术导航设置有价值,使用手术导航的中位偏好评分为3.7(3.3-4.0)(1-5分制),中位系统可用性评分为75(70-85)(0-100分制)。
手术导航可显著更好地定位和切除腹膜后的靶向LN。
本研究由KWF-阿尔卑斯山胡泽斯(NKI 2014-6596)以及荷兰癌症协会和荷兰卫生、福利与体育部的机构资助支持。